Bioprocess Technology Market Size Report | Growth Forecasts 2028

[Research Report] The bioprocess technology market size was valued at US$ 30,897.49 million in 2022 and is projected to reach US$ 77,090.05 million by 2028; it is estimated to register a CAGR of 16.8% from 2023 to 2028.

Analyst’s Viewpoint 

The advantages of bioprocess are using lower pressure, lower temperatures, and more conducive pH levels, and the entire process is renewable. Growing R&D spendings to introduce new drug compounds and increasing prevalence of chronic diseases. Stringent regulatory policies are the most impacting factors responsible for influential growth of the bioprocess technology market. Additionally, introducing advanced bioprocess technologies provide lucrative market opportunity for the overall market to grow exponentially during the forecast period. Further, emergence of Automated Real‐Time Flow Cytometry (ART‐FCM) acts as a future trend for the market to grow during 2023–2028. According to the segmentation profiled in the report, based on type segment, cell culture media bioprocess accounts a largest share; likewise, chromatography bioprocess is anticipated to register the highest CAGR during the forecast period (2023–2028). Furthermore, by modality, the single-use segment will account considerable share for the bioprocess technology during the forecast period. In terms of end user, the biopharmaceutical companies’ segment will dominate the bioprocess technology market growth during the forecast period. 

Bioprocess technology is a critical part of biotechnology that deals with processes combining living matter or its components with nutrients that produce specialty chemicals, reagents, and biotherapeutics. Different stages associated with bioprocess technology involve substrates and media preparation, biocatalyst selection and optimization, volume production, downstream processing, purification, and final processing. Bioprocess technology is widely used, from food and pharmaceuticals to fuel and chemicals.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Bioprocess Technology Market: Strategic Insights

Bioprocess Technology Market

• 
  CAGR (2022 - 2028)

  16.8%
• Market Size 2022
  US$ 30.9 Billion
• Market Size 2028
  US$ 77.09 Billion

Market Dynamics

GROWTH DRIVERS

• XXXXXXX
• XXXXXXX
• XXXXXXX

FUTURE TRENDS

• XXXXXXX
• XXXXXXX
• XXXXXXX

OPPORTUNITIES

• XXXXXXX
• XXXXXXX
• XXXXXXX

Key Players

• Merck KGaA
• Sartorius AG
• Thermo Fisher Scientific Inc
• Corning Inc
• STAMM Biotech
• Lonza Group AG
• Eppendorf SE
• Repligen Corp
• Danaher Corp

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

Type

• Cell Culture Media Bioprocess
• Chromatography Bioprocess
• Consumables & Accessories

Modality

• Single Use and Multiple Use

End User

• Academic & Medical Institutions
• Biopharmaceutical Companies
• Research Laboratories

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Market Insights

Growing R&D Spendings to Introduce New Drug Compounds

Pharmaceutical companies are spending huge sum in R&D to introduce new molecules with enhanced medical and commercial potency for various therapeutic applications. In the fiscal year 2019/2020, 16 pharmaceutical companies made it to the list of the world’s Top 50 companies in terms of total R&D investment. Novartis, Roche, Johnson & Johnson, Merck & Co, GlaxoSmithKline, and Pfizer are among the world’s Top 10 companies with high R&D investments.

R&D Investments by Major Pharmaceutical Companies

Company	R&D Investment in 2022 (US$ Million)	R&D Investment in 2021 (US$ Million)
Gilead Sciences Inc	27,305	27,281
Bristol-Myers Squibb Co	46,159	46,385
Amgen Inc.	26,323	25,979
Pfizer	100,330	81,288
Merck & Co	59,283	48,704
AbbVie Inc	58,054	56,197

Note: The currency conversion rates have been considered wherever required.

Source: Annual Reports of Companies and The Insight Partners Analysis

The patent expiry of blockbuster molecules, a limited number of potential products in the pipeline, and the increasing demand for biologics have driven companies to adopt novel technologies, such as single-use bioprocessing technologies, in order to facilitate a quick cost-effective turnaround process for products. Single-use component and system manufacturers typically produce and assemble products in clean rooms to ensure they do not introduce harmful particulates and endotoxins into a bioprocess. Thus, high investments in R&D are made to introduce new drug compounds and aid in the development of bioprocessing technologies; these technologies support emerging biomanufacturing capabilities and related interoperability of raw materials, bioreactors, and unit operations.

Type-Based Insights

Based on type, the bioprocess technology market is segmented into cell culture media bioprocess, chromatography bioprocess, consumables & accessories, and others. The cell culture media bioprocess segment held a largest market share of bioprocess technology in 2022 whereas chromatography bioprocess is anticipated to register a highest CAGR during the forecast period (2023–2028).

Modality-Based Insights

Based on modality, the global bioprocess technology market is bifurcated into single use and multiple use. The single use segment accounted a larger market share for bioprocess technology in 2022. The multiple use segment is expected to grow at a higher CAGR during the forecast period.

End User-Based Insights

In terms of end user, the bioprocess technology market is categorized into academic & medical institutions, biopharmaceutical companies, research laboratories, and others. The biopharmaceutical companies segment held a largest market share in 2022, whereas academic & medical institutions is expected to register a higher CAGR during the forecast period. 

Regional Analysis

North America dominated the bioprocess technology market accounting maximum share. The bioprocess technology market growth in this region is attributed due to the presence of large players launching innovative products (particularly related to bioprocess technology), growing product introduction in the region, and technological advancements in bioprocess technology. In North America, the US records maximum share for the bioprocess technology. According to the Food and Drug Administration (FDA) report, over 30 million people in the US suffer from ~7,000 rare diseases, accounting for life-threatening conditions with low treatment options. Drug, biological, and device development in the treatment of rare diseases is challenging due to a lack of understanding of the history of rare diseases and difficulty in conducting clinical trials. Therefore, the growth of bioprocess technologies such as gene and cell therapies (CGTs) and specialty pharmaceuticals represent a radical shift in the treatment of rare diseases. For example, CGTs have revealed significant health benefits than formulated drugs for treating rare diseases. In the US, more than 900 investigational new drug (IND) applications targeting gene therapy products are underway. Also, 10-20 gene therapies are approved annually by the FDA. Likewise, in August 2022, the FDA approved Bluebird Bio's "Zynteglo (betibeglogene autotemcel)." It was the most expensive single-application drug approval in the US intended for the treatment of a rare neurological disorder—cerebral adrenoleukodystrophy (CALD).

Likewise, Asia Pacific region will account highest CAGR for the bioprocess technology market. Among Asia Pacific region, China will hold considerable market share for the bioprocess technology market.  The bioprocessing capacity globally has increased at an average of 12% since the past decade, as per the BioPlan Associates Top 1000 Biofacility Index and Biomanufacturers Database report. China is well positioned as a global participant in markets with both small and large-molecule drugs, accounting for second and third position, respectively, worldwide. Also, China is home to several developers of cell and gene therapy due to China's base for contract development and manufacturing organizations (CDMOs), accounting for ~25% of the country's bioproduction capacity. Therefore, China has considerable biomanufacturing capabilities but strict adherence to the global GMP standards that build confidence in the biologics' safety and effectiveness.

Country	Biomanufacturing Facility (L)	Global Capacity (%)	Estimated Capacity CAGR (%)
China	1.77 million	10.2	15-20

Source: Global comparison of biomanufacturing capacity; data from the BioPlan Associates Top 1000 Biofacility Index and Biomanufacturers Database (CAGR = compound annual growth rate).

Bioprocess Technology Market Report Scope

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Merck KGaA, Sartorius AG, Thermo Fisher Scientific Inc, Corning Inc, STAMM Biotech, Lonza Group AG, Eppendorf SE, Repligen Corp, Danaher Corp, and BioPharma Dynamics Ltd are among the leading players operating in the global bioprocess technology market growth. Several other essential market players were analyzed for a holistic view of the market and its ecosystem. The report provides detailed market insights, which help the key players strategize their market growth. A few developments are mentioned below:

• In June 2022, Merck has entered a collaboration with Agilent Technologies to advance Process Analytical Technologies (PAT). PAT, which is strongly encouraged by global regulatory authorities, is a key enabler for real-time release and Bioprocessing 4.0.
• In March 2020, Sartorius launched BIOSTAT STR Generation 3 single-use bioreactor and BIOBRAIN automation platform to introduce innovations that will change the field of biopharmaceutical process development and manufacturing. Biostat STR simplifies biologics production.

Company Profiles

• Merck KGaA           
• Sartorius AG          
• Thermo Fisher Scientific Inc          
• Corning Inc            
• STAMM Biotech       
• Lonza Group AG      
• Eppendorf SE         
• Repligen Corp         
• Danaher Corp         
• BioPharma Dynamics Ltd